Evidence map›Paper›PMID 34795842›Full record

ArticleOxidative medicine and cellular longevity2021

Rh-CXCL-12 Attenuates Neuronal Pyroptosis after Subarachnoid Hemorrhage in Rats via Regulating the CXCR4/NLRP1 Pathway.

Ran Gu, Lu Wang, Hao Zhou, Xike Wang, Cameron Lenahan, Hao Qu, Yonghe Liu, Shirong Li, Changxiu Wei, Lu Han and 2 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Ran GuDepartment of Neurology, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Lu WangDepartment of Neurology, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Hao ZhouDepartment of Pediatric, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Xike WangDepartment of Pediatric, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Cameron LenahanBurrell College of Osteopathic Medicine, Las Cruces, NM 88003, USA.
Hao QuDepartment of Neurology, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Yonghe LiuDepartment of Clinical Laboratory, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Shirong LiDepartment of Neurology, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Changxiu WeiDepartment of Neurology, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Lu HanDepartment of Neurology, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Xiao HuDepartment of Neurology, Guizhou Provincial People's Hospital, Guiyang 550002, China.ORCID https://orcid.org/0000-0002-3216-6094
Gang ZuoDepartment of Neurosurgery, Taicang Hospital Affiliated to Soochow University, Taicang, Suzhou, Jiangsu 215400, China.ORCID https://orcid.org/0000-0002-2926-1023
Guizhou Provincial People's Hospital · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Subarachnoid hemorrhage (SAH) is a cerebrovascular disease associated with high morbidity and mortality. CXCR4 provides neuroprotective effects, which can alleviate brain injury and inflammation induced by stroke. Previous studies have suggested that CXCR4 reduces the pyroptosis of LPS-stimulated BV2 cells. The purpose of this study was to evaluate the antipyroptosis effects and mechanisms of CXCR4 after SAH. SAH animal model was induced via endovascular perforation. A total of 136 male Sprague-Dawley rats were used. Recombinant human cysteine-X-cysteine chemokine ligand 12 (rh-CXCL-12) was administered intranasally at 1 h after SAH induction. To investigate the underlying mechanism, the inhibitor of CXCR4, AMD3100, was administered intraperitoneally at 1 h before SAH. The neurobehavior tests were assessed, followed by performing Western blot and immunofluorescence staining. The Western blot results suggested that the expressions of endogenous CXCL-12, CXCR4, and NLRP1 were increased and peaked at 24 h following SAH. Immunofluorescence staining showed that CXCR4 was expressed on neurons, microglia, and astrocytes. Rh-CXCL-12 treatment improved the neurological deficits and reduced the number of FJC-positive cells, IL-18-positive neurons, and cleaved caspase-1(CC-1)-positive neurons after SAH. Meanwhile, rh-CXCL-12 treatment increased the levels of CXCL-12 and CXCR4, and reduced the levels of NLRP1, IL-18, IL-1

Indexed as

PyroptosisAnimalsBrain InjuriesChemokine CXCL12Disease Models, AnimalGene Expression RegulationInflammationMaleNerve Tissue ProteinsNeuronsRatsRats, Sprague-DawleyReceptors, CXCR4Signal TransductionSubarachnoid HemorrhageChemokine CXCL12CXCL12 protein, ratCxcr4 protein, ratNerve Tissue ProteinsNlrp1a protein, ratReceptors, CXCR4

Identifiers

PMID34795842
PMCPMC8595028
OpenAlexW3214668909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.